Entrada Therapeutics

TRDA70

$14.77arrow_drop_down1.53%-$0.23

TRDA70

$14.77

arrow_drop_down1.53%-$0.23

Performance History

Key Stats
Open	$15.12
Prev. Close	$14.86
EPS	3.02
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	14.93	15.19
52 Week Range	10.75	18.17

Ratios







EPS	3.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Entrada Therapeutics (TRDA)

Entrada Therapeutics, Inc. (TRDA) is a biotechnology company focused on developing novel therapeutics for patients with serious diseases. The company is committed to addressing unmet medical needs and improving patient outcomes through its innovative approach to drug discovery and development. Entrada's proprietary technology platform enables the delivery of therapeutics into cells and tissues that are traditionally difficult to target. By overcoming these barriers, Entrada aims to develop therapeutics that have the potential to make a significant impact on patient care.

One of the key factors that sets Entrada Therapeutics apart from its competitors is its smart analysis capabilities. The company utilizes advanced data analytics and machine learning techniques to analyze complex biological systems and identify potential drug targets. This approach enables Entrada to make more informed decisions about which candidates to pursue and helps to streamline the drug development process. With its smart analysis capabilities, Entrada is able to identify novel therapeutics that have the potential to address unmet medical needs and improve patient outcomes.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Dipal Doshi
Headquarters: Boston
Employees: 131
Exchange: NASDAQ

Keep an eye on Entrada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Entrada Therapeutics's (TRDA) price per share?

The current price per share for Entrada Therapeutics (TRDA) is $14.77. The stock has seen a price change of -$0.23 recently, indicating a -1.53% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Entrada Therapeutics (TRDA)?

For Entrada Therapeutics (TRDA), the 52-week high is $18.17, which is 23.02% from the current price. The 52-week low is $10.75, the current price is 37.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Entrada Therapeutics (TRDA) a growth stock?

Entrada Therapeutics (TRDA) has shown an average price growth of 0.41% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Entrada Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Entrada Therapeutics (TRDA) stock price performance year to date (YTD)?

As of the latest data, Entrada Therapeutics (TRDA) has a year-to-date price change of -2.64%. Over the past month, the stock has experienced a price change of -9.16%. Over the last three months, the change has been -2.89%. Over the past six months, the figure is 15.57%.

help

Is Entrada Therapeutics (TRDA) a profitable company?

Entrada Therapeutics (TRDA) has a net income of -$6.68M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 56.42% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $129.01M, although specific revenue growth data is currently not available. The gross profit is $126.17M. Operating income is noted at -$3.16M. Furthermore, the EBITDA is $96.87M.

help

What is the market capitalization of Entrada Therapeutics (TRDA)?

Entrada Therapeutics (TRDA) has a market capitalization of $557.99M. The average daily trading volume is 96.85K, indicating the stock's liquidity and investor engagement.